KYMERA THERAPEUTICS, INC. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
KYMERA THERAPEUTICS, INC. (KYMR) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $94.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes
us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2026-02-26
- KYMERA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2025 was $94.10M, a 27.16% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2024 was $74.00M, a 76.19% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2023 was $42.00M, a 0.24% decline from fiscal 2022.
- KYMERA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2022 was $42.10M, a 4.10% decline from fiscal 2021.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month |
|---|---|
| 2025-12-31 | $94.10M 10-K · filed 2026-02-26 |
| 2024-12-31 | $74.00M 10-K · filed 2025-02-27 |
| 2023-12-31 | $42.00M 10-K · filed 2024-02-22 |
| 2022-12-31 | $42.10M 10-K · filed 2023-02-23 |
| 2021-12-31 | $43.90M 10-K · filed 2022-02-24 |
| 2020-12-31 | $13.10M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |